- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 27, Issue 32, 2021
Current Pharmaceutical Design - Volume 27, Issue 32, 2021
Volume 27, Issue 32, 2021
-
-
Nano-Biomaterials as Sensing and Therapeutic Tool to Mitigate Viral Pathogenesis with Special Reference to COVID-19
Authors: Pallavi S. Chauhan, Dhananjay Yadav, Anuj Dubey and Jun-O JinIn order to treat severe acute respiratory syndrome coronavirus (SARS-CoV), till now, no such specific treatment is available. Various coronaviruses (CoV) such as SARS-CoV, MERS-CoV (Middle East Respiratory Syndrome), and SARS-CoV-2 can infect humans and the name was implicated due to their crown shape. SARS-CoV-2 is also called COVID-19 which was found to be a novel strain of coronavirus and is transmitted primarily t Read More
-
-
-
Coronavirus Disease -2019 (COVID-19) in 2020: A Perspective Study of a Global Pandemic
Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is responsible for the coronavirus disease- 2019 (COVID-19) pandemic, which was first reported from Wuhan, China, in late 2019. This infection spread to thousands of people globally within a short span of time with a progressive trend to mortality of citizens. Posing a potential public health threat, SARS-CoV-2 progressed from animal-to-human to human-tohuman Read More
-
-
-
Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options
Authors: Sayed S. Sohrab, Mohd Suhail, Mohammad A. Kamal and Esam I. AzharBackground: Viruses are known as the major causative agents for infectious diseases globally. The coronaviruses are one of the serious pathogens to cause serious diseases in humans. Recently identified SARSCoV- 2 from Wuhan City, China, has emerged as a serious threat to human health and caused a global pandemic. Bats have been confirmed as a primary source of infection. The vaccination of the human population and ani Read More
-
-
-
COVID-19: An Update on Pathogenesis and Treatment
Authors: Marwa A. AL Dhamen, Abrar F. Alhashim, Hawra H. Alqattan and Faheem H. PottooIn 2019, a new virus -SARS-COV2 possibly emerged in China, which infected many people affecting mainly the respiratory system. SARS-COV2 gets transmitted by inhalation of droplets from the infected persons. Symptoms start to appear after the incubation period of the virus which ranges from 2 to 14 days. In most people, symptoms are usually mild such as fever, sore throat, cough, chest tightness and fatigue. In other pe Read More
-
-
-
In Silico Studies Reveal Antiviral Effects of Traditional Indian Spices on COVID-19
Background: The global health emergency due to SARS-CoV-2 causing the COVID-19 pandemic emphasized the scientific community to intensify their research work for its therapeutic solution. In this study, Indian traditional spices owing to various medicinal properties were tested in silico for their inhibitory activity against SARS-CoV-2 proteins. SARS-CoV-2 spike proteins (SP) and main proteases (Mpro) play a significant role in i Read More
-
-
-
Silybin B and Cianidanol Inhibit Mpro and Spike Protein of SARS-CoV-2: Evidence from in silico Molecular Docking Studies
Background: The main proteases (Mpro) and Spike Proteins (SP) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) play a major role in viral infection development by producing several non-structural proteins (nsPs) and penetrating the host cells, respectively. In this study, the potential of in silico molecular docking-based drug repositioning approach was exploited for identifying the inhibitors of Mpro and SP of S Read More
-
-
-
In Silico Prediction and Designing of Potential siRNAs to be used as Antivirals Against SARS-CoV-2
Authors: Sayed S. Sohrab, Sherif A. El-Kafrawy, Aymn T. Abbas, Leena H. Bajrai and Esam I. AzharBackground: The unusual pneumonia outbreak that originated in the city of Wuhan, China in December 2019 was found to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19. Methods: In this work, we have performed an in silico design and prediction of potential siRNAs based on genetic diversity and recombination patterns, targeting various genes of SARS-CoV-2 for antiviral therapeut Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
- Issue 46
- Issue 45
- Issue 44
- Issue 43
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 4
- Issue 7
- Issue 6
- Issue 5
- Issue 3
- Issue 2
- Issue 1
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
